<DOC>
	<DOCNO>NCT01432028</DOCNO>
	<brief_summary>This cross-over , randomize clinical trial , objective evaluate effect low-dose oral hormone therapy non-oral hormone therapy endothelial function marker ( fibrinogen , von Willebrand factor , c-reactive protein ) , natriuretic peptide anthropometric , metabolic hormonal variable early healthy postmenopausal woman analyze polymorphisms estrogen receptor gene FTO polymorphisms Patients randomized receive oral hormone treatment non-oral hormone treatment The investigator hypothesis different genotype receptor estrogen gene FTO may influence treatment response metabolic marker cardiovascular risk</brief_summary>
	<brief_title>Pharmacogenetic Study Different Hormone Therapies Recent Menopause Women</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Inclusion criterion : last menstrual period 6 month 3 year begin study plus FSH level higher 35 IU/L ; age 42 58 year ; use medication know interfere hormonal , glucose , lipoprotein level past 3 month ; use steroidal steroidal antiinflammatory drug last 15 day . Exclusion criterion : patient diabetes , previous hysterectomy , endometrial thickness &gt; 0.5cm , history cancer , thromboembolism , establish cardiovascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>42 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>